Researchers at the Spanish National Cancer Research Center (CNIO) propose a new treatment for brain metastases that respond ...

Cancer immunotherapy has emerged as a groundbreaking approach in the field of medicine, significantly evolving over the past ...

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class ...

A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for ...

An oncologist tells PEOPLE about the innovative cancer treatment that extended the former president’s life as he celebrates ...

In a follow-up study, researchers compared cancer immunotherapy in mice, using either single or double immune responses. And ...

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) ...

Poster presentation details: Title: Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity ...

Thanks to early detection through widespread screening and dramatic breakthroughs in immunotherapy and other cancer ...

A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc.

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked, ...

A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...